atumelnant

Atumelnant is a first-in-class, orally bioavailable, nonpeptide antagonist of the adrenocorticotropic hormone (ACTH) receptor—specifically the melanocortin type 2 receptor (MC2R)—on the adrenal gland. Developed by Crinetics, it is designed to selectively block ACTH signaling at MC2R in the adrenal cortex. This inhibition reduces synthesis and secretion of steroid hormones such as cortisol and adrenal androgens. Atumelnant is being developed for diseases characterized by excess ACTH activity, including congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. Clinical studies have shown that once-daily oral administration leads to rapid and sustained reductions in key biomarkers like androstenedione (A4), 17-hydroxyprogesterone (17-OHP), serum cortisol, and urine free cortisol levels. The drug has demonstrated meaningful clinical improvements in CAH patients—including normalization of androgen levels—and significant reduction of hypercortisolemia in Cushing’s syndrome[1][3][4][5][6][7][8].

Other names

atumelnant